Drugs / IVX-0142
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00232999 | Oct → Dec 2005 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVX-0142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00232999 ↗ |
| Modality | Other / unclassified | “IVX-0142 is a heparin-derived hypersulfated disaccharide devoid of anticoagulant activity while possessing anti-allergic and anti-inflammatory activity in preclinical studies.” PMID 18699936 ↗ Sep 2008 |
| Route | Inhaled | “a single nebulized dose of IVX-0142 (80 mg)” PMID 18699936 ↗ Sep 2008 |